2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1656 Daratumumab combined with azacitidine plus venetoclax showed higher remission rate in unfit or heavily treated patients with oligoblastic relapse or refractory acute myeloid leukemia

Zongru Li, Lu Yu, MD2, Lijuan Hu3, Shasha Zhao4, Wenwen Li5, Xiaojun Huang, MD, PhD6, Qian Jiang Jr, MD7
1 Peking University People's Hospital, Beijing, China
2 Peking University People's Hospital, Beijing, China
3 Peking University People's Hospital, Beijing, China
4 Peking University People's Hospital, Qingdao, Shandong, China
5 Peking University People's Hospital, Qingdao, Shandong, China
6 Peking University People's Hospital, Beijing, China
7 Peking University People's Hospital, Beijing, China, Peking University People's Hospital, Qingdao, Shandong, China

Background  Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) have a poor prognosis. For those who are unfit for or resistant to intensive chemotherapy, current treatment options include targeted therapies or less intensive regimens. CD38 is widely expressed in AML, while its expression is relatively low on normal myeloid and lymphoid cells, making it a potential therapeutic target in AML. Data of CD38 monoantibody based therapy in R/R AML are limited.

Methods  In this retrospective study, patients with R/R AML who were unfit for or resistant to intensive chemotherapy and received daratumumab combined with azacitidine plus venetoclax were included. The regimen was as follows: daratumumab 16 mg/kg on days 0, 7, and 14; azacitidine 75 mg/m² on days 1–7, venetoclax 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3–28 (the dose of venetoclax should be adjusted according to the concomitant use of CYP3A inhibitors). Bone marrow (BM) assessment was performed on day 14; if BM blasts are <5%, the duration of venetoclax treatment is shortened to 14 days. The primary endpoint was the rate of complete remission with or without complete blood count recovery (CR/CRi). Second endpoints included CR, relapse-free survival, overall survival and adverse events.

Results  26 relapsed (n = 18) or refractory (n = 8) AML patients were included in this study. 17 (65%) were male. Median age was 65 years (interquartile range [IQR], 47–70 years). According to the 2022 ELN risk classification, 6 (23%), 5 (19%), and 15 (58%) patients were classified into the favorable-risk, intermediate-risk, and adverse-risk groups, respectively; the 2024 ELN risk classification, 17 (65%), 5 (19%), and 4 (15%), respectively. Before the treatment of daratumumab combined with AZA-VEN, the patients had received a median of 2 prior lines of therapy (IQR 1–3). Patients had previously received AZA-VEN (n = 21, 81%), intensive chemotherapy (n = 11, 42%), or CAG (n = 9, 35%). The median BM blasts before treatment was 23% (IQR, 9–39%). The percentage of leukemic blasts expressing CD38 was >60% in 24 patients and 40%–60% in 2 patients. Among the 26 patients, 24 received one cycle of daratumumab combined with venetoclax and azacitidine, and 2 received two cycles. Except one patient who died within 30 days, among the 25 evaluable patients, 10 patients (40%) achieved CR (n = 4) or CRi (n = 6), and 4 (16%) had a >50% reduction in BM blasts. With a median follow-up of 6 months (IQR, 4–8 months), 4 of 10 patients achieving CR/CRi received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 2 months and remained in CR. In those who did not receive allo-HSCT, 5 relapsed at a median of 2 months after achieving CR/CRi, and 1 received salvage allo-HSCT. 12 died of no response (n = 7), relapse (n =4) or infection (n = 1). The median relapse-free survival (RFS) was 3 months (95% CI, 2–4) or 5 months (95% CI, 2–8) when censoring at the time of allo-HSCT or not. The median overall survival (OS) was 11 (95% CI, 5–17) months. The incidences of febrile neutropenia, sepsis, pneumonia and invasive fungal infection were 52%, 4%, 20% and 12%, respectively.

The CR/CRi rate was higher in those with BM blasts <20% (7/11, 64%) compared with those with ≥20% (3/14, 21%, P = 0.03). There was no difference in the CR/CRi rate in the patients classified as favorable-, intermediate- and adverse-risk by ELN 2022 classification (20%, 20%, and 53%, P = 0.25) or by ELN 2024 classification (44%, 40%, 25%, P = 0.79).

Conclusion  Our study suggests daratumumab combined with azacitidine plus venetoclax represents an optimal bridging strategy to allo-HSCT for patients with R/R AML with BM blasts <20% who are ineligible for or resistant to intensive chemotherapy.

Zongru Li: No relevant conflicts of interest to declare.